Those in favor of the classification argue that excess fat accumulation/distribution is linked to sustained and serious ...

Policymakers should focus on both obesity prevention and better access to treatment for those already living with obesity.

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

Obesity remains a global health crisis, often linked to serious diseases such as diabetes, heart disease, and fatty liver ...

RFK Jr., the nation’s new health secretary, has cited “highly chemically processed foods” as a chief culprit behind an ...

Drinking sugar-sweetened beverages may increase your risk of heart disease. These drinks are easy to overconsume and provide ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

Decades of research and news articles espousing an “obesity epidemic” and tons of weight-loss products launched under the ...

Currently, there are six FDA approved weight loss medications. They include three GLP-1 receptor agonists -- liraglutide ...

Fatty liver disease, medically called metabolic dysfunction-associated steatotic liver disease (MASLD), affects millions ...